Theriva Biologics (NYSEAMERICAN:TOVX) Releases Earnings Results

Theriva Biologics (NYSEAMERICAN:TOVX) released its quarterly earnings data on Thursday. The company reported $1.30 EPS for the quarter, FiscalAI reports.

Theriva Biologics Price Performance

TOVX opened at $0.18 on Friday. The company has a market capitalization of $5.91 million, a price-to-earnings ratio of -0.01 and a beta of 0.54. The company has a current ratio of 0.90, a quick ratio of 0.90 and a debt-to-equity ratio of 0.25. Theriva Biologics has a 12-month low of $0.16 and a 12-month high of $1.50. The business’s fifty day simple moving average is $0.20 and its 200-day simple moving average is $0.28.

Hedge Funds Weigh In On Theriva Biologics

A hedge fund recently raised its stake in Theriva Biologics stock. Geode Capital Management LLC increased its holdings in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) by 651.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 212,087 shares of the company’s stock after buying an additional 183,878 shares during the quarter. Geode Capital Management LLC owned 0.63% of Theriva Biologics worth $45,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 6.17% of the stock is owned by institutional investors.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.